108 related articles for article (PubMed ID: 17387689)
61. Biphasic effect of apomorphine, an anti-parkinsonian drug, on bladder function in rats.
Uchiyama T; Sakakibara R; Yoshiyama M; Yamamoto T; Ito T; Liu Z; Yamaguchi C; Awa Y; Yano HM; Yanagisawa M; Yamanishi T; Hattori T; Kuwabara S
Neuroscience; 2009 Sep; 162(4):1333-8. PubMed ID: 19501134
[TBL] [Abstract][Full Text] [Related]
62. Kinetics of fibril formation of bovine kappa-casein indicate a conformational rearrangement as a critical step in the process.
Leonil J; Henry G; Jouanneau D; Delage MM; Forge V; Putaux JL
J Mol Biol; 2008 Sep; 381(5):1267-80. PubMed ID: 18616951
[TBL] [Abstract][Full Text] [Related]
63. Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2(High) receptors.
Seeman P
Synapse; 2007 Dec; 61(12):1013-8. PubMed ID: 17853435
[TBL] [Abstract][Full Text] [Related]
64. Mechanism of docosahexaenoic acid-induced inhibition of in vitro Abeta1-42 fibrillation and Abeta1-42-induced toxicity in SH-S5Y5 cells.
Hossain S; Hashimoto M; Katakura M; Miwa K; Shimada T; Shido O
J Neurochem; 2009 Oct; 111(2):568-79. PubMed ID: 19686246
[TBL] [Abstract][Full Text] [Related]
65. The midbrain slice preparation. An in vitro model to select potential anti-parkinsonian drugs?
Guatteo E; Cucchiaroni ML; Sebastianelli L; Bernardi G; Mercuri NB
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S150-3. PubMed ID: 18583176
[TBL] [Abstract][Full Text] [Related]
66. Anti-amyloidogenic activity of S-allyl-L-cysteine and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro.
Gupta VB; Rao KS
Neurosci Lett; 2007 Dec; 429(2-3):75-80. PubMed ID: 18023978
[TBL] [Abstract][Full Text] [Related]
67. Characterization of alpha-synuclein interactions with selected aggregation-inhibiting small molecules.
Rao JN; Dua V; Ulmer TS
Biochemistry; 2008 Apr; 47(16):4651-6. PubMed ID: 18366183
[TBL] [Abstract][Full Text] [Related]
68. Site-Specific Fluorescence Polarization for Studying the Disaggregation of α-Synuclein Fibrils by Small Molecules.
Haney CM; Cleveland CL; Wissner RF; Owei L; Robustelli J; Daniels MJ; Canyurt M; Rodriguez P; Ischiropoulos H; Baumgart T; Petersson EJ
Biochemistry; 2017 Feb; 56(5):683-691. PubMed ID: 28045494
[TBL] [Abstract][Full Text] [Related]
69. A hyperbranched dopamine-containing PEG-based polymer for the inhibition of α-synuclein fibrillation.
Breydo L; Newland B; Zhang H; Rosser A; Werner C; Uversky VN; Wang W
Biochem Biophys Res Commun; 2016 Jan; 469(4):830-5. PubMed ID: 26707645
[TBL] [Abstract][Full Text] [Related]
70. Pergolide mesylate form II.
Jegorov A; Horák Z; Cejka J; Kratochvíl B; Císarová I
Acta Crystallogr C; 2003 Oct; 59(Pt 10):O575-6. PubMed ID: 14532675
[TBL] [Abstract][Full Text] [Related]
71. Trihexyphenidyl dependence-report of two cases.
Michael A; Murali T; Mathai PJ; Gopinath PS
Indian J Psychiatry; 1984 Apr; 26(2):178-9. PubMed ID: 21965980
[TBL] [Abstract][Full Text] [Related]
72. Amyloid Disassembly: What Can We Learn from Chaperones?
Almeida ZL; Brito RMM
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36552032
[TBL] [Abstract][Full Text] [Related]
73. Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.
Naoi M; Maruyama W; Shamoto-Nagai M
J Neural Transm (Vienna); 2020 Feb; 127(2):131-147. PubMed ID: 31993732
[TBL] [Abstract][Full Text] [Related]
74. Effect of L-DOPA/Benserazide on Propagation of Pathological α-Synuclein.
Shimozawa A; Fujita Y; Kondo H; Takimoto Y; Terada M; Sanagi M; Hisanaga SI; Hasegawa M
Front Neurosci; 2019; 13():595. PubMed ID: 31258461
[TBL] [Abstract][Full Text] [Related]
75. Rosmarinic acid suppresses Alzheimer's disease development by reducing amyloid β aggregation by increasing monoamine secretion.
Hase T; Shishido S; Yamamoto S; Yamashita R; Nukima H; Taira S; Toyoda T; Abe K; Hamaguchi T; Ono K; Noguchi-Shinohara M; Yamada M; Kobayashi S
Sci Rep; 2019 Jun; 9(1):8711. PubMed ID: 31213631
[TBL] [Abstract][Full Text] [Related]
76. α-Synuclein Heterocomplexes with β-Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity.
Daniele S; Frosini D; Pietrobono D; Petrozzi L; Lo Gerfo A; Baldacci F; Fusi J; Giacomelli C; Siciliano G; Trincavelli ML; Franzoni F; Ceravolo R; Martini C; Bonuccelli U
Front Mol Neurosci; 2018; 11():53. PubMed ID: 29520218
[TBL] [Abstract][Full Text] [Related]
77. The Oligomer Hypothesis in α-Synucleinopathy.
Ono K
Neurochem Res; 2017 Dec; 42(12):3362-3371. PubMed ID: 28828740
[TBL] [Abstract][Full Text] [Related]
78. Anti-amyloid compounds inhibit α-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA).
Herva ME; Zibaee S; Fraser G; Barker RA; Goedert M; Spillantini MG
J Biol Chem; 2014 Apr; 289(17):11897-11905. PubMed ID: 24584936
[TBL] [Abstract][Full Text] [Related]
79. The Aggregation of Huntingtin and α-Synuclein.
Chánez-Cárdenas ME; Vázquez-Contreras E
J Biophys; 2012; 2012():606172. PubMed ID: 22899913
[TBL] [Abstract][Full Text] [Related]
80. Multiple system atrophy: current and future approaches to management.
Flabeau O; Meissner WG; Tison F
Ther Adv Neurol Disord; 2010 Jul; 3(4):249-63. PubMed ID: 21179616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
